Remyelination Trials
Are We Expecting the Unexpected?
Citation Manager Formats
Make Comment
See Comments

Abstract
Neuroaxonal loss is believed to underpin the progressive disability that characterizes multiple sclerosis (MS). While focal inflammatory demyelination is a principal cause of acute axonal transection and subsequent axonal degeneration, the gradual attrition of permanently demyelinated axons may also contribute to tissue damage, particularly in the progressive phase of the disease. Therefore, remyelination is considered a putative neuroprotective strategy. In this article, we review the potential pitfalls of remyelination trials, provide a framework for their appropriate design and temper the expectations, at times unrealistic, of researchers, regulators and the pharmaceutical industry.
Glossary
- DMT=
- disease-modifying therapy;
- FIDID=
- Feline Irradiated Diet-Induced Demyelination;
- MS=
- multiple sclerosis;
- PMD=
- Pelizaeus Merzbacher Disease
Footnotes
The Article Processing Charge was funded by the authors.
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
- Received March 20, 2021.
- Accepted in final form June 14, 2021.
- Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Articles
Optical coherence tomography and disease subtype in multiple sclerosisM. Pulicken, E. Gordon-Lipkin, L. J. Balcer et al.Neurology, November 26, 2007 -
Article
Chronic demyelination exacerbates neuroaxonal loss in patients with MS with unilateral optic neuritisYuyi You, Michael H. Barnett, Con Yiannikas et al.Neurology: Neuroimmunology & Neuroinflammation, March 13, 2020 -
Articles
Diagnostic accuracy of retinal abnormalities in predicting disease activity in MSJorge Sepulcre, Manuel Murie-Fernandez, Angel Salinas-Alaman et al.Neurology, April 30, 2007 -
Article
No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MSMarco Pisa, Simone Guerrieri, Giovanni Di Maggio et al.Neurology, November 15, 2017